DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Stelara (Ustekinumab) - Published Studies

 
 



Stelara Related Published Studies

Well-designed clinical trials related to Stelara (Ustekinumab)

Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS). [2013]

An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. [2012]

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. [2012]

Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. [2012]

Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. [2012]

Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis. [2011.11.30]

Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial. [2011.09.29]

Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). [2011.09]

Bounded outcome score modeling: application to treating psoriasis with ustekinumab. [2011.08]

Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective. [2011.07]

Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. [2011.04]

Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasis. [2011.04]

The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients. [2011.01]

Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective. [2011]

Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). [2011]

Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasis. [2011]

Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2. [2011]

Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: a meta-analysis. [2011]

Population pharmacokinetics of ustekinumab in patients with active psoriatic arthritis. [2010.12]

Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial. [2010.10]

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. [2010.09]

Review of the safety and efficacy of ustekinumab. [2010.09]

Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis. [2010.07]

Effects of ustekinumab administration on primate/human antigen-recall and humoral immune response functions. [2010.06]

Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters. [2010.05]

Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis. [2010.03]

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. [2010.01.14]

Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. [2010.01]

Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial. [2010]

Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters. [2010]

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. [2010]

Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis. [2010]

Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. [2010]

Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. [2009.11]

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. [2009.02.21]

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. [2008.10]

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. [2008.09]

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). [2008.05.17]

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). [2008.05.17]

Well-designed clinical trials possibly related to Stelara (Ustekinumab)

Cost-efficacy comparison of biological therapies for patients with moderate to severe psoriasis in Japan. [2013]

Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. [2013]

Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. [2011.09.12]

Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. [2011.09]

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. [2011.08.24]

Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? [2009.03]

Other research related to Stelara (Ustekinumab)

Efficacy and safety of mildronate for acute ischemic stroke: a randomized, double-blind, active-controlled phase II multicenter trial. [2013]

Treatment with 311-nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intraindividual trial. [2012]

Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: a meta-analysis. [2011.12]

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials. [2011.10.04]

Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. [2011.09.17]

311-nm ultraviolet B-enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intraindividual trial. [2011.09.12]

Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis. [2011.09.10]

Responses to ustekinumab in the anti-TNF agent-naive vs. anti-TNF agent-exposed patients with psoriasis vulgaris. [2011.09]

Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials. [2011.07]

Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis. [2011.06]

New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab. [2011.04.01]

Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives. [2011.03]

Ustekinumab for the treatment of psoriasis. [2011.03]

Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab. [2011.01.10]

Ustekinumab and herpes zoster. [2011]

Ganciclovir ophthalmic gel 0.15%: in acute herpetic keratitis (dendritic ulcers). [2011]

Ustekinumab for the treatment of psoriasis. [2011]

Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. [2010.10]

Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis. [2010.07]

Ustekinumab for the treatment of psoriasis: review of three multicenter clinical trials. [2010.04]

The use of ustekinumab in autoimmune disease. [2010.04]

Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. [2010.03]

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. [2010]

Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases. [2009.12]

Ustekinumab for the treatment of moderate to severe psoriasis. [2009.10]

Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis. [2009.09]

Ustekinumab: a new option in psoriasis therapy. [2009.06.18]

Ustekinumab. [2009.05]

Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. [2009.02]

Ustekinumab in the therapy of chronic plaque psoriasis. [2009]

Ustekinumab. [2009]

Other possibly related research studies

Comparing biological therapies in psoriasis: implications for clinical practice. [2010.10]

The future of biological therapies. [2010.03]

Treating multiple sclerosis with monoclonal antibodies: a 2010 update. [2010.05]

New drug therapies for multiple sclerosis. [2010.06]

Specific immune intervention with monoclonal antibodies for the treatment of multiple sclerosis. [2010]

The status of biologic therapies in the treatment of moderate to severe psoriasis. [2009.10]

Targeting the interleukin-12/23 cytokine family in the treatment of psoriatic disease. [2008.12]

Long-term efficacy of biologics in the treatment of psoriasis: what do we really know? [2009.09]

Could anti IL12/23 therapy replace anti-TNF biologics? [2009]

Safety of conventional systemic agents and biologic agents in the treatment of psoriasis. [2009.09]

Biologics in the treatment of psoriasis: clinical and economic overview. [2009.09]

[Molecular target drug development for curing multiple sclerosis] [2009.08]

Update on the treatment of peripheral arthritis in psoriatic arthritis. [2009.08]

[Biologic therapies in chronic inflammatory bowel diseases] [2009.05]

Overview of biologic therapy for Crohn's disease. [2009.08]

Biologic survival. [2009.04]

Treatments for psoriasis and the risk of malignancy. [2009.06]

[Biologic therapies in the treatment of psoriasis] [2009.05]

Management of moderate to severe plaque psoriasis (part 2): clinical update on T-cell modulators and investigational agents. [2009.03]

New biologics for psoriasis and psoriatic arthritis. [2009.01]

IL-12/IL-23 inhibitors: the advantages and disadvantages of this novel approach for the treatment of psoriasis. [2008.11]

Gateways to clinical trials. [2008.05]

Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. [2011.10.21]

Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. [2011.09]

Cytokine modulators in the treatment of sarcoidosis. [2011.12]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014